This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, Imcheck Therapeutics Sas, Institut Jean Paoli & Irène Calmettes. Active years: 2025.
Company Filing History:
1 out of 5,383 
1 out of 4 
1 out of 32 
Years Active: 2025
Title: Magali Colazet: Innovator in Cancer Treatment
Introduction
Magali Colazet is a prominent inventor based in Marseilles, France. She has made significant contributions to the field of cancer treatment through her innovative research and development of novel therapeutic agents. Her work focuses on the activation of specific immune responses to combat cancer disorders.
Latest Patents
Magali Colazet holds a patent for BTN3A binding proteins and their uses. This patent discloses anti-BTN3A activating antibody fragments that specifically bind to BTN3A and activate the cytolytic function of Vγ9/Vδ2 T cells. The invention relates to specific anti-BTN3A binding proteins comprising such activating antibody fragments and their application in the manufacturing of novel drugs aimed at treating cancer disorders, particularly those cancers that can be effectively treated with activated γδ T cells. She has 1 patent to her name.
Career Highlights
Throughout her career, Magali has worked with notable organizations such as Imcheck Therapeutics SAS and Institut Jean Paoli & Irene Calmettes. Her experience in these institutions has allowed her to advance her research and contribute to the development of innovative cancer therapies.
Collaborations
Magali has collaborated with esteemed colleagues, including Alemseged Truneh and Christine Pasero. These partnerships have further enriched her research and expanded the impact of her work in the field of oncology.
Conclusion
Magali Colazet is a trailblazer in the development of cancer treatments, with her innovative approaches and patented technologies paving the way for new therapeutic options. Her dedication to advancing medical science continues to inspire and influence the field of cancer research.